Novo Nordisk Drops 'Nordisk' in Major Rebrand to Combat Eli Lilly

Key points

• Novo Nordisk will use 'Novo' as its primary brand name, though 'Novo Nordisk A/S' remains the legal entity.
• The rebrand includes a new logo with the Apis bull facing right and a new corporate culture framework called 'The Novo Way.'
• The company aims to address a 15% stock decline and a significant market share gap, holding 38.8% versus Eli Lilly’s 60.9% in the second quarter.
• New operational principles focus on simplified workflows, clear priorities, and maintaining patient safety and ethics.
• The rebrand follows recent setbacks in cardiovascular drug trials and a strategic pivot to simplify its semaglutide product lineup.

Background

This rebranding effort comes after a series of significant setbacks for Novo Nordisk in 2026. The company recently halted multiple late-stage trials for its anti-inflammatory drug ziltivekimab, including the Hermes and Athena studies, after data monitoring committees indicated a low probability of success. These failures, alongside the scrapped Zeus trial, have raised concerns about the company's ability to expand beyond its core obesity and diabetes franchises. Additionally, Novo had previously retired the Rybelsus brand name to consolidate its oral semaglutide offerings under the Ozempic and Wegovy names, signaling an earlier shift toward simplified branding.

How outlets are covering it

CNBC highlights the rebrand as a strategic response to stiff competition from Eli Lilly and investor pressure to deliver new blockbuster products, noting the 15% drop in shares despite the oral Wegovy's success. Fierce Pharma frames the move as a necessary 'slimming down' of the brand, comparing it to historical rebrands by GSK and Sanofi, and emphasizes the cultural shift toward a 'faster, more competitive and increasingly consumer-driven market.' While both sources agree on the competitive pressure from Eli Lilly, CNBC focuses on the financial and market share metrics, whereas Fierce Pharma focuses on the cultural and branding evolution, noting the change in the logo's direction as a symbolic nod to the future. The third source, FirstWord Pharma, was inaccessible due to a JavaScript error and provided no additional information.

Why it matters

The rebrand signals a critical pivot for Novo Nordisk as it struggles to maintain its dominance in the obesity drug market against Eli Lilly. With market share significantly eroded and multiple drug trials failing, the company is attempting to reset its corporate culture and public perception to regain investor confidence and competitive momentum. The success of this cultural and branding overhaul will be crucial in determining whether Novo can reverse its stock decline and sustain long-term growth in a highly competitive landscape.

What to watch

Novo Nordisk is scheduled to detail its business strategy changes during a Capital Markets Day event on September 21. The company will likely monitor the impact of the new 'Novo Way' principles on operational efficiency and market share recovery. Investors will watch for signs that the rebrand translates into tangible competitive advantages against Eli Lilly's expanding portfolio, including its Foundayo pill.